<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22015" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Gabapentin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yasaei</surname>
            <given-names>Rama</given-names>
          </name>
          <aff>UCLA Kern Medical</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Katta</surname>
            <given-names>Shravan</given-names>
          </name>
          <aff>Texas Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rama Yasaei declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shravan Katta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22015.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Gabapentin is an anticonvulsive medication that received approval from the US Food and Drug Administration (FDA) in 1993 and has been available in generic form in the USA since 2004.&#x000a0;Gabapentin&#x000a0;was originally used as a muscle relaxant and&#x000a0;an anti-spasmodic. However, it was later discovered&#x000a0;that gabapentin has the potential of an anticonvulsive medication and can be used as an adjunct to more potent anticonvulsants. The medication also proves beneficial in managing certain types of neural pain and psychiatric disorders. As its applications have broadened, there is a growing demand for interprofessional collaboration among primary care, neurology, anesthesiology, and other pertinent specialties. This activity outlines the indications, mechanisms of action, administration, significant adverse effects, contraindications, monitoring, and characteristics of gabapentin toxicity. This activity also provides clinicians with the necessary skills and tools to treat various types of muscular, neurological, and psychiatric medical conditions, both acute and chronic, thereby improving patients' quality of life.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for gabapentin therapy, including neuropathic pain, partial onset seizures, restless legs syndrome, and other relevant neurological and psychiatric conditions.</p></list-item><list-item><p>Screen patients for risk factors and contraindications&#x000a0;before initiating gabapentin therapy, such as renal impairment, history of substance misuse, or concurrent medication interactions.</p></list-item><list-item><p>Apply patient-centered approaches to gabapentin prescribing, tailoring dosage adjustments and treatment plans based on individual needs and preferences.</p></list-item><list-item><p>Collaborate with interprofessional healthcare team members to optimize gabapentin therapy by coordinating comprehensive patient care and addressing emerging clinical concerns or treatment adjustments.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22015&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22015">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22015.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Gabapentin is an anticonvulsive medication that was first discovered in the 1970s.<xref ref-type="bibr" rid="article-22015.r1">[1]</xref>&#x000a0;The medication received approval from the US Food and Drug Administration (FDA) in 1993 and has been available in generic form in the USA since 2004. Gabapentin&#x000a0;was originally used as a muscle relaxant and&#x000a0;an anti-spasmodic. However, it was later discovered&#x000a0;that gabapentin has the potential of an anticonvulsive medication and can be used as an adjunct to more potent anticonvulsants.<xref ref-type="bibr" rid="article-22015.r2">[2]</xref><xref ref-type="bibr" rid="article-22015.r3">[3]</xref><xref ref-type="bibr" rid="article-22015.r4">[4]</xref>&#x000a0;The medication also proves beneficial in managing certain types of neural pain and psychiatric disorders.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p><bold>Gabapentin:&#x000a0;</bold>Gabapentin is indicated for postherpetic neuralgia and serves as adjunctive therapy for managing partial seizures (with or without secondary generalization) in adults and pediatric patients aged 3&#x000a0;or older.</p>
        <p><bold>Gabapentin enacarbil:</bold> Gabapentin enacarbil is indicated for postherpetic neuralgia and moderate-to-severe restless legs syndrome (RLS).<xref ref-type="bibr" rid="article-22015.r5">[5]</xref></p>
        <p><bold>Gabapentin for neuropathic pain-postherpetic neuralgia:&#x000a0;</bold>The Canadian Pain Society, National Institute for Health and Care Excellence, and Neuropathic Pain Special Interest Group recommend using gabapentin as one of the initial treatment options for neuropathic pain.<xref ref-type="bibr" rid="article-22015.r6">[6]</xref>&#x000a0;European Federation of Neurological Societies also endorses its use for postherpetic neuralgia.<xref ref-type="bibr" rid="article-22015.r6">[6]</xref>&#x000a0;The FDA also approved gabapentin for managing postherpetic neuralgia in adults. Recently, gabapentin underwent systemic evaluation in the management of diabetic neuropathy.</p>
        <p>In 1998, Rowbotham and his research team concluded that in 229 postherpetic neuralgia patients, gabapentin had more significant pain reduction as early as&#x000a0;2 weeks after initiating the treatment. Furthermore, other measurements of mood, depression, anger-hostility, fatigue, and physical functioning were more effectively managed with gabapentin compared to a placebo. During the same time, Backonja et al reviewed the effect of gabapentin in 165 diabetic neuropathy patients. They showed that pain reduction in the gabapentin group is greater (as measured with an 11-point Likert scale) in comparison to the placebo group. The results were significant from 2 weeks of initiation of therapy and stayed significant during the&#x000a0;8 weeks of study. Patients in the treatment group also reported improvement in their quality of life. This medication was well tolerated in 67% of patients who received a maximum daily dosage of 3600 mg.<xref ref-type="bibr" rid="article-22015.r7">[7]</xref><xref ref-type="bibr" rid="article-22015.r8">[8]</xref></p>
        <p><bold>Gabapentin for partial seizures:&#x000a0;</bold>According to the guidelines from the American Epilepsy Society, clinicians might consider gabapentin as a potential option for patients aged 60 and older with new-onset focal epilepsy, as it could be similarly effective and better tolerated compared to carbamazepine.<xref ref-type="bibr" rid="article-22015.r9">[9]</xref></p>
        <p><bold>Gabapentin for restless leg syndrome:&#x000a0;</bold>The American Academy of Sleep Medicine (AASM) suggests the use of gabapentin for the management of moderate-to-severe RLS.<xref ref-type="bibr" rid="article-22015.r10">[10]</xref>&#x000a0;Furthermore, The American Academy of Neurology (AAN) substantiates the efficacy of gabapentin enacarbil in mitigating symptoms of moderate-to-severe primary RLS. This slow-release gabapentin prodrug reduces International Restless Legs Syndrome (IRLS) Study Group Rating Scale scores and significantly improves subjective sleep quality.<xref ref-type="bibr" rid="article-22015.r11">[11]</xref></p>
        <p>
<bold>Off-Label&#x000a0;Uses</bold>
</p>
        <p>Gabapentin&#x000a0;is used&#x000a0;off-label use for fibromyalgia, bipolar disorder, anxiety disorders, resistant depressants, mood disorders, irritable bowel syndrome, alcohol withdrawal, postoperative analgesia, migraine prophylaxis, interstitial cystitis, painful diabetic neuropathy, social phobia, generalized tonic-clonic seizures, pruritus, insomnia, posttraumatic stress disorder (PTSD), and refractory chronic cough and postmenopausal vasomotor symptoms.<xref ref-type="bibr" rid="article-22015.r12">[12]</xref><xref ref-type="bibr" rid="article-22015.r13">[13]</xref><xref ref-type="bibr" rid="article-22015.r14">[14]</xref></p>
        <p><bold>Gabapentin in alcohol withdrawal:&#x000a0;</bold>For the first time, the DSM-V includes the diagnostic guidelines for alcohol dependency. A variety of severe conditions result from or are influenced by alcohol dependence, including stomach ulcers, liver disorders, increased risk of heart disease, and neuropathy. Researchers assess that 3.8% of worldwide deaths result from direct or indirect effects of alcohol misuse.<xref ref-type="bibr" rid="article-22015.r15">[15]</xref>&#x000a0;While gabapentin's mechanism of action is generally understood, it appears to be a pharmacologic option for treating issues involving the gamma-aminobutyric acid (GABA) receptor system. Gabapentin is a relatively safe, readily available, and effective drug for alcohol-use disorder treatment, specifically for the abstinence maintenance phase. A study published in 2015 showed evidence for gabapentin use in treating alcohol withdrawal and dependence.<xref ref-type="bibr" rid="article-22015.r16">[16]</xref></p>
        <p>Gabapentin has also demonstrated a statistical benefit when used as adjunctive therapy to naltrexone (the FDA-approved alcohol use disorder medication). Higher doses of gabapentin, 1800 mg/d, seem to have a stronger effect on alcohol-use disorder abstinence maintenance. However, the trials investigating gabapentin as monotherapy have shown mixed results. For gabapentin, unlike disulfiram and naltrexone, no need for hepatic dose adjustments is evidenced. Gabapentin can also be used in patients with renal function below 20 mg/dl (although a dosing adjustment is needed).&#x000a0;A 2018 clinical review examined gabapentin and other drugs as anti-craving therapy in alcohol use disorder. The author felt a need for clinicians to expand their therapeutic choices to other drugs beyond those with FDA approval for this condition, including gabapentin.<xref ref-type="bibr" rid="article-22015.r17">[17]</xref>&#x000a0;</p>
        <p>A double-blind study investigated the use of up to 1200 mg/d of gabapentin compared to a placebo in alcohol use disorder. The research suggested that gabapentin&#x000a0;is the most effective following the initiation of abstinence as a means to sustain abstinence; it might be most effective in patients with a history of more severe alcohol withdrawal symptoms.<xref ref-type="bibr" rid="article-22015.r18">[18]</xref>&#x000a0;Another study examined using up to 1200 mg of gabapentin vs. benzodiazepine; the researchers found gabapentin superior to lorazepam in treating outpatients with moderate alcohol withdrawal. This outcome was measured by a lower chance of drinking and a superior but clinically similar alcohol withdrawal symptom reduction.<xref ref-type="bibr" rid="article-22015.r19">[19]</xref>&#x000a0;</p>
        <p>According to the 2020 ASAM (The American Society of Addiction Medicine) guidelines for alcohol withdrawal management, benzodiazepines are typically the initial treatment due to their proven ability to reduce withdrawal symptoms effectively. Gabapentin is a viable option for managing alcohol withdrawal, particularly when clinicians plan to continue its use as part of the patient's treatment for alcohol use disorder.&#x000a0;Gabapentin is also a suitable choice when the use of benzodiazepines is contraindicated.<xref ref-type="bibr" rid="article-22015.r20">[20]</xref>&#x000a0;Moreover, per the American Psychiatric Association (APA) guidelines, consider gabapentin or topiramate for patients with moderate-to-severe alcohol use disorder aiming to reduce consumption or achieve abstinence, especially if naltrexone and acamprosate are intolerant or ineffective.<xref ref-type="bibr" rid="article-22015.r21">[21]</xref></p>
        <p><bold>Gabapentin in the treatment of anxiety and depression:&#x000a0;</bold>Gabapentin is sometimes prescribed off-label for patients with bipolar disorder to reduce anxiety levels or for anxiety disorders. Clinicians have also used it for patients who have anxiety and depression. A 2015 systematic review examined the available study data on gabapentin use for psychological disorders. Further research is necessary to determine whether gabapentin has a place in treating such conditions. The authors found evidence suggesting gabapentin may benefit certain anxiety disorders but noted no studies have been conducted on its effectiveness for generalized anxiety disorder. They also determined that evidence showed that gabapentin is less likely to benefit as an adjunct in treating bipolar disorder. Their research determined that gabapentin has clearer efficacy for alcohol craving and withdrawal symptoms and may be an adjunct to treating opioid dependence. They found no clear evidence for gabapentin therapy in depression, PTSD prevention, OCD, or other types of substance abuse.<xref ref-type="bibr" rid="article-22015.r22">[22]</xref>&#x000a0;</p>
        <p>In 2019, researchers conducted another systematic review examining gabapentin's role in treating substance abuse and psychiatric disorders. Their findings were that gabapentin appears to have some efficacy in certain forms of anxiety disorder, such as pre-operative anxiety and anxiety in breast cancer survivors, as well as social phobia. They concluded that additional clinical trials with larger patient populations were needed to support using gabapentin in psychiatric disorders, especially since multiple clinical trials in their analysis were open-label trials with inherently less rigorous statistical analysis.<xref ref-type="bibr" rid="article-22015.r23">[23]</xref></p>
        <p><bold>Gabapentin in movement disorders:&#x000a0;</bold>Gabapentin was investigated for amyotrophic lateral&#x000a0;sclerosis (ALS), but contemporary evidence shows no benefit. Gabapentin can be used for certain movement disorders, such as essential tremors and RLS.&#x000a0;In 1996, Miller et al treated 152 ALS patients randomly assigned to receive 2400 mg gabapentin daily compared to a placebo group. Results showed a slower decline in muscle strength in the treatment group. Further research indicated that gabapentin is ineffective in patients with ALS.<xref ref-type="bibr" rid="article-22015.r24">[24]</xref>&#x000a0;According to a 2017 systematic review conducted by Diana et al, gabapentin's efficacy in treating ALS appears nonsignificant. Evidence indicates that gabapentin does not provide survival benefits, delay the decline in muscle strength, or slow respiratory function deterioration.<xref ref-type="bibr" rid="article-22015.r25">[25]</xref>&#x000a0;</p>
        <p>In 1998, Pahwa et al reviewed the efficacy of gabapentin in treating essential tremors compared to a placebo. The first 14 days of the study showed no difference between patients receiving 1800 mg gabapentin daily compared to placebo. But in 2000, Ondo&#x000a0;completed 6 weeks of research on a group of patients receiving up to 3600 mg/d of gabapentin in contrast to the placebo, and patients demonstrated significant improvements in self-report scores for tremor, observed tremor scores, and daily activity improvement scores.&#x000a0;According to AAN, gabapentin monotherapy is probably effective for essential tremors.<xref ref-type="bibr" rid="article-22015.r26">[26]</xref></p>
        <p>In 1997, Olson and his team performed a 1-month double-blind, placebo-controlled evaluation of the efficacy of gabapentin in 19 patients with advanced Parkinsonism who were suffering from rigidity and bradykinesia. The treatment group received a total daily dosage of 1200 mg of gabapentin. The results in this group were superior to the placebo group in reducing rigidity and bradykinesia as measured by the United Parkinson Disease Rating Scale. The treatment group showed a significant reduction in tremors.<xref ref-type="bibr" rid="article-22015.r27">[27]</xref>&#x000a0;Limited evidence suggests the possible use of gabapentin for neuropathic pain associated with Parkinsonism.<xref ref-type="bibr" rid="article-22015.r28">[28]</xref>&#x000a0;Gabapentin has also been used off-label for antipsychotic-induced akathisia; propranolol is typically considered the first-line treatment.<xref ref-type="bibr" rid="article-22015.r29">[29]</xref><xref ref-type="bibr" rid="article-22015.r30">[30]</xref><xref ref-type="bibr" rid="article-22015.r31">[31]</xref><xref ref-type="bibr" rid="article-22015.r32">[32]</xref></p>
      </sec>
      <sec id="article-22015.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Although the exact mechanism of action with the GABA receptors is unknown, researchers know that gabapentin freely passes the blood-brain barrier and acts on neurotransmitters. Gabapentin has a cyclohexyl group to the structure of the neurotransmitter GABA as a chemical structure. Although it has a structure similar to GABA, it does not bind to GABA receptors or influence the synthesis or uptake of GABA. Gabapentin works by showing a high affinity for binding sites throughout the brain&#x000a0;corresponding to the presence of the voltage-gated calcium channels, especially &#x003b1;-2-&#x003b4;-1, which seems to inhibit the release of excitatory neurotransmitters in the presynaptic area&#x000a0;that participate in epileptogenesis.</p>
        <p>No evidence exists for direct action at the serotonin, dopamine, benzodiazepine, or histamine receptors; research has shown gabapentin to increase total blood levels of serotonin in healthy control subjects.<xref ref-type="bibr" rid="article-22015.r33">[33]</xref>&#x000a0;Gabapentin's mechanism in RLS is unclear, but it is known to bind strongly to &#x003b1;2&#x003b4;-subunits of voltage-activated calcium channels. This binding likely inhibits calcium entry, normalizing neurotransmitter release, including excitatory glutamate; however, the precise mechanism remains unknown.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Increasing gabapentin's dosage leads to reduced bioavailability; for example, daily doses of 900 mg, 1200 mg, 2400 mg, 3600 mg, and 4800 mg yield bioavailability of approximately 60%, 47%, 34%, 33%, and 27%, respectively. The impact of food is minor, resulting in a 14% increase in area under the curve (AUC) and Cmax. The variable bioavailability of gabapentin may be due to transporter saturation at clinical doses. The limitations in oral absorption&#x000a0;are overcome with the development of its prodrug, gabapentin enacarbil, transported via high-capacity sodium-dependent multivitamin transporter (SMVT) and monocarboxylate transporter 1 (MCT1) in the intestine. The peak plasma concentration for gabapentin is 2 to 4 hours. The time to peak plasma concentration for gabapentin enacarbil is 5 hours for subjects in a fasting state and 7.3&#x000a0;hours for under-fed conditions.<xref ref-type="bibr" rid="article-22015.r14">[14]</xref></p>
        <p><bold>Distribution:</bold> Plasma protein binding of gabapentin is less than 3%. The mean apparent volume of distribution is around 58&#x000b1;6 L. Gabapentin is highly lipophilic; cerebrospinal fluid concentrations in patients with epilepsy are approximately 20% of the corresponding levels found in plasma, highlighting its capacity to cross the blood-brain barrier.</p>
        <p><bold>Metabolism:</bold> In humans, gabapentin undergoes minimal metabolic alteration, largely retaining&#x000a0;the original structure. Gabapentin does not induce or inhibit CYP enzymes. Also, none of the CYP enzyme inhibitors alter their pharmacokinetics. Gabapentin enacarbil undergoes substantial first-pass hydrolysis through non-specific carboxylesterase activity, primarily within enterocytes and, to a lesser degree, in hepatocytes. This process leads to the formation of gabapentin, carbon dioxide, acetaldehyde, and isobutyric acid.<xref ref-type="bibr" rid="article-22015.r34">[34]</xref></p>
        <p><bold>Elimination:</bold> Systemic elimination of gabapentin primarily occurs through renal excretion. The elimination half-life of gabapentin is 5 to 7 hours, and it takes&#x000a0;2 days for the body to eliminate gabapentin from its system. The elimination rate constant, as well as plasma and renal clearance, correlate directly with creatinine clearance. Reduced clearance of gabapentin is observed in older adults and those with renal dysfunction. Effective removal from plasma is achieved through hemodialysis. Gabapentin is a substrate of organic cation transporter type-2 (OCT2).<xref ref-type="bibr" rid="article-22015.r33">[33]</xref></p>
      </sec>
      <sec id="article-22015.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Gabapentin&#x000a0;is available in 2 forms&#x02014;gabapentin immediate release and the prodrug gabapentin enacarbil. Gabapentin is available in tablet form with strengths of 600 mg and 800 mg, capsules in strengths of 100 mg, 300 mg, and 400 mg, as well as an oral solution of 250 mg/5mL. Gabapentin enacarbil is available in 300 mg extended-release tablets.<xref ref-type="bibr" rid="article-22015.r35">[35]</xref></p>
        <p>
<bold>Dosages</bold>
</p>
        <p>Initial treatment with gabapentin typically begins with a dosage of 300 mg/d, which is gradually increased to 3 times daily, with a maximum dosage of 4800 mg/d. Healthcare providers recommend initiating the first dose in the evening and then taking the medication 3 times daily.&#x000a0;The effects of gabapentin are usually noticeable within the first week of treatment, although significant improvement may take up to a month in some cases. When discontinuing the medication, it is advised to taper the dose over more than 7 days.</p>
        <p><bold>Partial seizures:</bold> The recommended dosage of gabapentin ranges from 300 to 1200 mg taken orally 3 times daily, with a maximum daily dosage of 3600 mg.</p>
        <p><bold>Post-herpetic neuralgia:</bold> The recommended dosage of gabapentin ranges from 300 to 600 mg taken orally 3 times daily, with a maximum daily dosage of 1800 mg.</p>
        <p><bold>Restless legs syndrome (gabapentin enacarbil):</bold>&#x000a0;The recommended dosage of&#x000a0;gabapentin enacarbil is 600 mg taken orally once daily, with a maximum daily dosage of 1800 mg.<xref ref-type="bibr" rid="article-22015.r5">[5]</xref>&#x000a0;</p>
        <p><bold>Neuropathic pain:</bold>&#x000a0;The recommended gabapentin dosage ranges from 300 to 1200 mg taken orally 3 times daily, with a maximum daily dosage of 3600 mg.</p>
        <p><bold>Fibromyalgia:</bold> The recommended gabapentin dosage is between 400&#x000a0;and 800 mg taken orally 3 times daily, with a maximum daily dosage of 2400 mg.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>The American Association for the Study of Liver Disease (AASLD) recognizes the potential role of gabapentin as a primary non-opioid therapeutic choice, particularly for managing neuropathic pain in patients with cirrhosis.<xref ref-type="bibr" rid="article-22015.r36">[36]</xref></p>
        <p><bold>Renal impairment: </bold>For patients with renal impairment, gabapentin, which is primarily excreted really and lacks active metabolites, requires dosage adjustment. Therefore, it is crucial to modify both the dose amount and frequency accordingly.</p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance of 30 mL/min to 60 mL/min: 200 mg to 700 mg twice per day</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance of 16 mL/min to 29 mL/min: 200 mg to 700 mg once daily</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance of 15 mL/min: 100 mg to 300 mg once daily</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance of less than 15 mL/min on hemodialysis: 125 mg to 350 mg as a supplement dose post-hemodialysis</p>
          </list-item>
        </list>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>A cohort study utilizing the US Medicaid dataset investigated gabapentin exposure during pregnancy from January 2000 to December 2013. While no significant associations were observed with major malformations, multiple administration of gabapentin was correlated with an increase in the risk of cardiac defects. Late or dual exposure to gabapentin is linked to an increased risk of small for gestational age and preterm birth.&#x000a0;Additionally, the risk of neonatal intensive care unit (NICU) admission increased with higher drug exposure levels.<xref ref-type="bibr" rid="article-22015.r37">[37]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Limited data suggest that maternal doses of gabapentin up to 2.1&#x000a0;g daily result in relatively low levels in infant serum. Administration of a single dose of 300 or 600 mg to mothers before cesarean section did not impact breastfeeding. It is advisable to monitor infants for drowsiness, sufficient weight gain, and developmental milestones, particularly in younger, exclusively breastfed infants and when combining anticonvulsant or psychotropic drugs.<xref ref-type="bibr" rid="article-22015.r38">[38]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>The FDA has not approved gabapentin for treating partial seizures in pediatric patients aged 3 or younger. Gabapentin can be considered for pain relief in terminally ill children.<xref ref-type="bibr" rid="article-22015.r35">[35]</xref></p>
        <p><bold>Older patients:&#x000a0;</bold>Given the tendency for reduced renal function among older patients, careful consideration in dosing is advisable, with necessary adjustments as per creatinine clearance.</p>
      </sec>
      <sec id="article-22015.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Gabapentin may cause certain adverse effects, which are listed below.</p>
        <p><bold>Severe reactions:</bold> The severe adverse reactions include suicidality, depression, Stevens-Johnson syndrome, anaphylaxis, angioedema, erythema multiforme, rhabdomyolysis, and withdrawal seizure or withdrawal symptoms if the drug is discontinued abruptly.<xref ref-type="bibr" rid="article-22015.r39">[39]</xref></p>
        <p><bold>More common reactions:&#x000a0;</bold>More common reactions to gabapentin include ataxia, dizziness, fatigue, somnolence, fever, nystagmus, peripheral edema, hostility, hyperkinesia (in pediatric patients), nausea, vomiting, tremor, asthenia, diplopia, diarrhea, xerostomia, infection, amblyopia, headache, constipation, weight gain, abnormal thinking, amnesia, back pain, impotence, and depression.</p>
        <p>In a study analyzing adverse drug reactions associated with gabapentin through the FDA Adverse Events Reporting System, it was found that compared to duloxetine, gabapentin showed a higher likelihood of drug withdrawal, auditory hallucinations, delusions, euphoric mood, ataxia, aggression, and substance use disorder.<xref ref-type="bibr" rid="article-22015.r40">[40]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Antiepileptic drugs:&#x000a0;</bold>An important benefit of gabapentin is no interaction with valproate, lithium, and carbamazepine exists. However, concurrent use of gabapentin and pregabalin is contraindicated.<xref ref-type="bibr" rid="article-22015.r41">[41]</xref></p>
        <p><bold>Opioids:&#x000a0;</bold>Reports of respiratory depression and sedation, occasionally fatal, have emerged with the coadministration of gabapentin and opioids like morphine, hydrocodone, oxycodone, and buprenorphine.<xref ref-type="bibr" rid="article-22015.r42">[42]</xref></p>
        <p><bold>Antacids:&#x000a0;</bold>Concurrent use of an antacid containing magnesium and aluminum hydroxides reduces gabapentin bioavailability. To mitigate this interaction, gabapentin is recommended at least 2 hours after administering the antacid.<xref ref-type="bibr" rid="article-22015.r43">[43]</xref></p>
        <p><bold>Drug or laboratory test interactions:&#x000a0;</bold>Gabapentin's addition to other antiepileptic drugs might lead to false positive readings of urinary protein. Thus, the sulfosalicylic acid precipitation test is recommended to assess urine protein presence accurately.</p>
      </sec>
      <sec id="article-22015.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Gabapentin should not be prescribed to individuals with a history of allergic reactions to the drug or excipients.<xref ref-type="bibr" rid="article-22015.r44">[44]</xref><xref ref-type="bibr" rid="article-22015.r45">[45]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p><bold>DRESS/multiorgan hypersensitivity:</bold> In addressing Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), or multiorgan hypersensitivity, a reasonable strategy involves the cessation of gabapentin unless an alternate etiology can be definitively established. Notably, instances of severe, and in some cases fatal, multiorgan hypersensitivity reactions have been observed in conjunction with the utilization of gabapentin. Bullous pemphigoid has also been reported.<xref ref-type="bibr" rid="article-22015.r46">[46]</xref></p>
        <p><bold>Anaphylaxis and angioedema:</bold> Rapid intervention is important upon the presentation of anaphylaxis or angioedema, necessitating the immediate discontinuation of gabapentin. Such hypersensitivity reactions carry the potential for life-threatening consequences and warrant prompt medical evaluation and treatment.<xref ref-type="bibr" rid="article-22015.r47">[47]</xref></p>
        <p><bold>Driving impairment, somnolence or sedation, and dizziness:</bold> A cautious approach advises individuals undergoing gabapentin treatment to exercise restraint in operating vehicles until they comprehensively understand&#x000a0;the&#x000a0;potential to impair driving capabilities. Notably, gabapentin has demonstrated the capacity to induce drowsiness, sedation, and dizziness.<xref ref-type="bibr" rid="article-22015.r48">[48]</xref></p>
        <p><bold>Increased seizure frequency:</bold> Prudent clinical practice underscores the avoidance of abrupt discontinuation of gabapentin, particularly among individuals with epilepsy, as this may engender an elevation in seizure frequency. Gradual dose tapering is advocated as a strategy to mitigate this inherent risk.</p>
        <p><bold>Respiratory depression:</bold> A comprehensive understanding of gabapentin and central nervous system depressants, notably opioids, is critical, given the potential for developing profound respiratory depression. Individualized dosage adjustments are essential to managing this risk.<xref ref-type="bibr" rid="article-22015.r42">[42]</xref></p>
        <p><bold>Neuropsychiatric adverse reactions (children aged 3 to 12):</bold> Pediatric subjects aged 3 to 12 receiving gabapentin treatment for epilepsy warrant meticulous monitoring for potential neuropsychiatric sequelae, encompassing emotional lability, hostility, thought disorder, and hyperkinesia.</p>
        <p><bold>Withdrawal seizures and status epilepticus:</bold> Discontinuing antiepileptic drugs, including gabapentin, necessitates a gradual tapering regimen to prevent the risk of withdrawal-induced seizures or the emergence of status epilepticus.<xref ref-type="bibr" rid="article-22015.r49">[49]</xref></p>
      </sec>
      <sec id="article-22015.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Clinicians should check baseline creatinine levels before and during the treatment. Patients should be informed and screened for depression, behavioral changes, and suicidality.<xref ref-type="bibr" rid="article-22015.r39">[39]</xref><xref ref-type="bibr" rid="article-22015.r50">[50]</xref>&#x000a0;Before prescribing gabapentin or other pharmacotherapy, clinicians should check for iron deficiency, as it is associated with RLS.<xref ref-type="bibr" rid="article-22015.r51">[51]</xref></p>
      </sec>
      <sec id="article-22015.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>At the federal level, gabapentin is not classified as a controlled substance, is regarded as a non-addictive medication, and is recognized by the Centers for Disease Control and Prevention (CDC) as a potential substitute for opioids in managing chronic pain. However, growing concerns about the potential for misuse are increasing.<xref ref-type="bibr" rid="article-22015.r52">[52]</xref>&#x000a0;Several US states have moved gabapentin to the Schedule V controlled substance category. Gabapentin does not have a high risk of an overdose but can increase the euphoria caused by opioids and reduce drug withdrawals. An Australian study examined fatal gabapentinoid-related poisoning and discovered that concomitant other drug use is almost universal in such cases.<xref ref-type="bibr" rid="article-22015.r53">[53]</xref>&#x000a0;Furthermore, gabapentin can bypass the blocking effects of addiction treatment medications and, unfortunately, does not appear in urine drug tests.<xref ref-type="bibr" rid="article-22015.r54">[54]</xref>&#x000a0;</p>
        <p>Gabapentin toxicity is seen in those with chronic kidney disease or undergoing hemodialysis, showing symptoms like tremors, altered mental states, and respiratory depression requiring intubation. Reports of rhabdomyolysis due to gabapentin have been described.<xref ref-type="bibr" rid="article-22015.r55">[55]</xref><xref ref-type="bibr" rid="article-22015.r56">[56]</xref>&#x000a0;No antidote for gabapentin poisoning currently exists.&#x000a0;Gabapentin can be removed through dialysis. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup recommends refraining from utilizing extracorporeal treatments (ECTR) and standard care for gabapentin poisoning in patients with normal kidney function. However, if reduced kidney function and coma necessitating mechanical ventilation are evident, the EXTRIP suggests incorporating ECTR and standard care.<xref ref-type="bibr" rid="article-22015.r57">[57]</xref></p>
      </sec>
      <sec id="article-22015.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Gabapentin is widely prescribed by various healthcare providers, including primary care providers, nurse practitioners, physician assistants, neurologists, internists, and orthopedic surgeons, to address various medical conditions. Apart from its anticonvulsant properties, the drug serves multiple purposes. While gabapentin is generally considered safe, pharmacists play a crucial role in assisting the healthcare team and monitoring patients' medication regimens to prevent potential drug interactions. In a documented case, a patient with diabetes, diabetic neuropathy, and hypertension was prescribed both gabapentin and pregabalin, resulting in adverse effects. Upon intervention by the pharmacist, the physician was contacted, leading to the successful discontinuation of pregabalin. This scenario underscores the importance of effective communication among healthcare professionals in safeguarding patient well-being and achieving favorable treatment outcomes.<xref ref-type="bibr" rid="article-22015.r41">[41]</xref>&#x000a0;</p>
        <p>Nursing staff can address patient inquiries, review dosing information, and act as a liaison for clinicians. Notably, all members of the interprofessional team must recognize&#x000a0;the potential for gabapentin misuse. Severe RLS cases may necessitate referral to a movement disorder specialist for gabapentin use. The role of psychiatrists is crucial in effectively managing the conditions that patients experience during alcohol withdrawal. Referral to an epileptologist may be warranted for gabapentin usage in refractory seizure cases. In instances of severe overdose, consultation with a critical care physician and admission to the medical intensive care unit (MICU) may be imperative. Adopting an interprofessional team approach with transparent communication among clinicians, specialists, pharmacists, and nurses is vital for enhancing patient outcomes associated with gabapentin therapy while mitigating potential adverse effects.</p>
      </sec>
      <sec id="article-22015.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22015&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22015">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22015/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22015">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22015.s11">
        <title>References</title>
        <ref id="article-22015.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lumsden</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Basu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Amin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>DeAlwis</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lodh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lundy</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Mordekar</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cadwgan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological management of abnormal tone and movement in cerebral palsy.</article-title>
            <source>Arch Dis Child</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>104</volume>
            <issue>8</issue>
            <fpage>775</fpage>
            <page-range>775-780</page-range>
            <pub-id pub-id-type="pmid">30948360</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rocha</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferraz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prud&#x000ea;ncio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Costa-Rodrigues</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Differential effects of antiepileptic drugs on human bone cells.</article-title>
            <source>J Cell Physiol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>234</volume>
            <issue>11</issue>
            <fpage>19691</fpage>
            <page-range>19691-19701</page-range>
            <pub-id pub-id-type="pmid">30941778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chin</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Asch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Seto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hernandez-Boussard</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Integrating Adjuvant Analgesics into Perioperative Pain Practice: Results from an Academic Medical Center.</article-title>
            <source>Pain Med</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>161</fpage>
            <page-range>161-170</page-range>
            <pub-id pub-id-type="pmid">30933284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viniol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ploner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hickstein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Haasenritter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donner-Banzhoff</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Prescribing practice of pregabalin/gabapentin in pain therapy: an evaluation of German claim data.</article-title>
            <source>BMJ Open</source>
            <year>2019</year>
            <month>Mar</month>
            <day>30</day>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>e021535</fpage>
            <pub-id pub-id-type="pmid">30928920</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garcia-Borreguero</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>H&#x000f6;gl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bainbridge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Buchfuhrer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hadjigeorgiou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Inoue</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Manconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Winkelmann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation.</article-title>
            <source>Sleep Med</source>
            <year>2016</year>
            <month>May</month>
            <volume>21</volume>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">27448465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruccu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Truini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A review of Neuropathic Pain: From Guidelines to Clinical Practice.</article-title>
            <source>Pain Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>Suppl 1</issue>
            <fpage>35</fpage>
            <page-range>35-42</page-range>
            <pub-id pub-id-type="pmid">29178033</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kneib</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Sibbett</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Carrougher</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Muffley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Gibran</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Mandell</surname>
                <given-names>SP</given-names>
              </name>
            </person-group>
            <article-title>The Effects of Early Neuropathic Pain Control With Gabapentin on Long-Term Chronic Pain and Itch in Burn Patients.</article-title>
            <source>J Burn Care Res</source>
            <year>2019</year>
            <month>Jun</month>
            <day>21</day>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>457</fpage>
            <page-range>457-463</page-range>
            <pub-id pub-id-type="pmid">30893433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Backonja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beydoun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LaMoreaux</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Garofalo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial.</article-title>
            <source>JAMA</source>
            <year>1998</year>
            <month>Dec</month>
            <day>02</day>
            <volume>280</volume>
            <issue>21</issue>
            <fpage>1831</fpage>
            <page-range>1831-6</page-range>
            <pub-id pub-id-type="pmid">9846777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanner</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ashman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Harden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bautista</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Abou-Khalil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Burakgazi-Dalkilic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hirtz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nespeca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gidal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Faught</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>French</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the American Epilepsy Society and the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</article-title>
            <source>Epilepsy Curr</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>260</fpage>
            <page-range>260-268</page-range>
            <pub-id pub-id-type="pmid">30254527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aurora</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Kristo</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bista</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Rowley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zak</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Lamm</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>RS</given-names>
              </name>
              <collab>American Academy of Sleep Medicine</collab>
            </person-group>
            <article-title>The treatment of restless legs syndrome and periodic limb movement disorder in adults--an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline.</article-title>
            <source>Sleep</source>
            <year>2012</year>
            <month>Aug</month>
            <day>01</day>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1039</fpage>
            <page-range>1039-62</page-range>
            <pub-id pub-id-type="pmid">22851801</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winkelman</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Allen</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Trenkwalder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Gloss</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zesiewicz</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Dec</month>
            <day>13</day>
            <volume>87</volume>
            <issue>24</issue>
            <fpage>2585</fpage>
            <page-range>2585-2593</page-range>
            <pub-id pub-id-type="pmid">27856776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perloff</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Berlin</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Gillette</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petersile</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kurowski</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin in Headache Disorders: What Is the Evidence?</article-title>
            <source>Pain Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>162</fpage>
            <page-range>162-71</page-range>
            <pub-id pub-id-type="pmid">26398728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <article-title>Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society.</article-title>
            <source>Menopause</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1155</fpage>
            <page-range>1155-72; quiz 1173-4</page-range>
            <pub-id pub-id-type="pmid">26382310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Goldenberg</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Lalonde</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sandhu</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Welge</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Hess</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.</article-title>
            <source>Arthritis Rheum</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>56</volume>
            <issue>4</issue>
            <fpage>1336</fpage>
            <page-range>1336-44</page-range>
            <pub-id pub-id-type="pmid">17393438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warren</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prescription Drug and Alcohol Use Disorders: Alcohol Use Disorder.</article-title>
            <source>FP Essent</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>478</volume>
            <fpage>30</fpage>
            <page-range>30-42</page-range>
            <pub-id pub-id-type="pmid">30844223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hall-Flavin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schak</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>The role of gabapentin in the management of alcohol withdrawal and dependence.</article-title>
            <source>Ann Pharmacother</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>49</volume>
            <issue>8</issue>
            <fpage>897</fpage>
            <page-range>897-906</page-range>
            <pub-id pub-id-type="pmid">25969570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Anticraving therapy for alcohol use disorder: A clinical review.</article-title>
            <source>Neuropsychopharmacol Rep</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>105</fpage>
            <page-range>105-116</page-range>
            <pub-id pub-id-type="pmid">30175522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anton</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Latham</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Voronin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Book</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Prisciandaro</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bristol</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.</article-title>
            <source>JAMA Intern Med</source>
            <year>2020</year>
            <month>May</month>
            <day>01</day>
            <volume>180</volume>
            <issue>5</issue>
            <fpage>728</fpage>
            <page-range>728-736</page-range>
            <pub-id pub-id-type="pmid">32150232</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myrick</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Malcolm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Boyle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Anton</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>1582</fpage>
            <page-range>1582-8</page-range>
            <pub-id pub-id-type="pmid">19485969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <article-title>The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management.</article-title>
            <source>J Addict Med</source>
            <year>2020</year>
            <season>May/Jun</season>
            <volume>14</volume>
            <issue>3S Suppl 1</issue>
            <fpage>1</fpage>
            <page-range>1-72</page-range>
            <pub-id pub-id-type="pmid">32511109</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reus</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bukstein</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Eyler</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Hilty</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Horvitz-Lennon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahoney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pasic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weaver</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wills</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kidd</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yager</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>175</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-90</page-range>
            <pub-id pub-id-type="pmid">29301420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berlin</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Perloff</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin Therapy in Psychiatric Disorders: A Systematic Review.</article-title>
            <source>Prim Care Companion CNS Disord</source>
            <year>2015</year>
            <volume>17</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">26835178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bachu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kotapati</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adnan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Farooq</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Zubair</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Qamar</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Begum</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review.</article-title>
            <source>Front Psychiatry</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>228</fpage>
            <pub-id pub-id-type="pmid">31133886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Gelinas</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Dronsky</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mendoza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barohn</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bryan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ravits</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Neville</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ringel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bromberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petajan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Jackson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mandler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bosch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sorenson</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Kelkar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Olney</surname>
                <given-names>R</given-names>
              </name>
              <collab>Western ALS Study Group</collab>
            </person-group>
            <article-title>Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.</article-title>
            <source>Neurology</source>
            <year>2001</year>
            <month>Apr</month>
            <day>10</day>
            <volume>56</volume>
            <issue>7</issue>
            <fpage>843</fpage>
            <page-range>843-8</page-range>
            <pub-id pub-id-type="pmid">11294919</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bongioanni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>O'Keeffe</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jan</month>
            <day>09</day>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>CD006049</fpage>
            <pub-id pub-id-type="pmid">28067943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zesiewicz</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Elble</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Louis</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Gronseth</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Ondo</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Dewey</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Okun</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Weiner</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology.</article-title>
            <source>Neurology</source>
            <year>2011</year>
            <month>Nov</month>
            <day>08</day>
            <volume>77</volume>
            <issue>19</issue>
            <fpage>1752</fpage>
            <page-range>1752-5</page-range>
            <pub-id pub-id-type="pmid">22013182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olson</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Gruenthal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial.</article-title>
            <source>Am J Med</source>
            <year>1997</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-6</page-range>
            <pub-id pub-id-type="pmid">9209202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buhmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kassubek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jost</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Management of Pain in Parkinson's Disease.</article-title>
            <source>J Parkinsons Dis</source>
            <year>2020</year>
            <volume>10</volume>
            <issue>s1</issue>
            <fpage>S37</fpage>
            <page-range>S37-S48</page-range>
            <pub-id pub-id-type="pmid">32568113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeshima</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ishikawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kanbayashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin enacarbil for antipsychotic induced akathisia in schizophrenia patients: a pilot open-labeled study.</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2018</year>
            <volume>14</volume>
            <fpage>3179</fpage>
            <page-range>3179-3184</page-range>
            <pub-id pub-id-type="pmid">30538475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sullivan</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Wilbur</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin pharmacotherapy for antipsychotic-induced akathisia: single-patient experiment and case report.</article-title>
            <source>Ther Adv Psychopharmacol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>4</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-2</page-range>
            <pub-id pub-id-type="pmid">24688760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albert</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Catthoor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Morrens</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Akathisia after chronic usage of synthetic cathinones: A case study.</article-title>
            <source>Front Psychiatry</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>1046486</fpage>
            <pub-id pub-id-type="pmid">36620653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pringsheim</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Addington</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martino</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Morgante</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ricciardi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Poole</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>TRE</given-names>
              </name>
            </person-group>
            <article-title>The Assessment and Treatment of Antipsychotic-Induced Akathisia.</article-title>
            <source>Can J Psychiatry</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>63</volume>
            <issue>11</issue>
            <fpage>719</fpage>
            <page-range>719-729</page-range>
            <pub-id pub-id-type="pmid">29685069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chincholkar</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice.</article-title>
            <source>Br J Pain</source>
            <year>2020</year>
            <month>May</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>104</fpage>
            <page-range>104-114</page-range>
            <pub-id pub-id-type="pmid">32537149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kume</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin enacarbil for the treatment of moderate to severe primary restless legs syndrome (Willis-Ekbom disease): 600 or 1,200 mg dose?</article-title>
            <source>Neuropsychiatr Dis Treat</source>
            <year>2014</year>
            <volume>10</volume>
            <fpage>249</fpage>
            <page-range>249-62</page-range>
            <pub-id pub-id-type="pmid">24523590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galloway</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yaster</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pain and symptom control in terminally ill children.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>711</fpage>
            <page-range>711-46</page-range>
            <pub-id pub-id-type="pmid">10835999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rakoski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goyal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spencer-Safier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weissman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Volk</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pain management in patients with cirrhosis.</article-title>
            <source>Clin Liver Dis (Hoboken)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>135</fpage>
            <page-range>135-140</page-range>
            <pub-id pub-id-type="pmid">30992804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patorno</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hernandez-Diaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huybrechts</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mogun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bateman</surname>
                <given-names>BT</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin in pregnancy and the risk of adverse neonatal and maternal outcomes: A population-based cohort study nested in the US Medicaid Analytic eXtract dataset.</article-title>
            <source>PLoS Med</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>e1003322</fpage>
            <pub-id pub-id-type="pmid">32870921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r38">
          <label>38</label>
          <element-citation publication-type="book">
            <chapter-title>Gabapentin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>11</month>
            <day>30</day>
            <pub-id pub-id-type="pmid">30000283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen Burns</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kinge</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stokke Opdal</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johannessen</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Johannessen Landmark</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring of gabapentin in various indications.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2019</year>
            <month>May</month>
            <volume>139</volume>
            <issue>5</issue>
            <fpage>446</fpage>
            <page-range>446-454</page-range>
            <pub-id pub-id-type="pmid">30710348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vickers-Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Charnigo</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Lofwall</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>206</volume>
            <fpage>107709</fpage>
            <pub-id pub-id-type="pmid">31732295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghayur</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Potential Adverse Consequences of Combination Therapy with Gabapentin and Pregabalin.</article-title>
            <source>Case Rep Med</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>5559981</fpage>
            <pub-id pub-id-type="pmid">34122553</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gomes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Antoniou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mamdani</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Paterson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>van den Brink</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case-control study.</article-title>
            <source>PLoS Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e1002396</fpage>
            <pub-id pub-id-type="pmid">28972983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yagi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mino</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Umemura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawakami</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Impact of concomitant antacid administration on gabapentin plasma exposure and oral bioavailability in healthy adult subjects.</article-title>
            <source>Drug Metab Pharmacokinet</source>
            <year>2012</year>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>248</fpage>
            <page-range>248-54</page-range>
            <pub-id pub-id-type="pmid">22240839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fletcher</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Butcher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raw</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Naqvi</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin and hypersensitivity syndrome.</article-title>
            <source>J Postgrad Med</source>
            <year>2007</year>
            <season>Oct-Dec</season>
            <volume>53</volume>
            <issue>4</issue>
            <fpage>276</fpage>
            <page-range>276-7</page-range>
            <pub-id pub-id-type="pmid">18097126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ragucci</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin-induced hypersensitivity syndrome.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2001</year>
            <season>Mar-Apr</season>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>103</fpage>
            <page-range>103-5</page-range>
            <pub-id pub-id-type="pmid">11307046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flamm</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sachdev</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dufresne</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin-Induced Bullous Pemphigoid.</article-title>
            <source>J Am Osteopath Assoc</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>191</fpage>
            <page-range>191-193</page-range>
            <pub-id pub-id-type="pmid">28241331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chong</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>TH</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin-Induced Angioedema of Tongue.</article-title>
            <source>J Acute Med</source>
            <year>2021</year>
            <month>Jun</month>
            <day>01</day>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>72</fpage>
            <page-range>72-73</page-range>
            <pub-id pub-id-type="pmid">34295638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vickers Smith</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lofwall</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Quiroz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Staton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Havens</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>A qualitative analysis of gabapentin misuse and diversion among people who use drugs in Appalachian Kentucky.</article-title>
            <source>Psychol Addict Behav</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-121</page-range>
            <pub-id pub-id-type="pmid">29239621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrueto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Howland</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin withdrawal presenting as status epilepticus.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2002</year>
            <volume>40</volume>
            <issue>7</issue>
            <fpage>925</fpage>
            <page-range>925-8</page-range>
            <pub-id pub-id-type="pmid">12507063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rentsch</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Morford</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Fiellin</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Bryant</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Justice</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Tate</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Safety of Gabapentin Prescribed for Any Indication in a Large Clinical Cohort of 571,718 US Veterans with and without Alcohol Use Disorder.</article-title>
            <source>Alcohol Clin Exp Res</source>
            <year>2020</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>9</issue>
            <fpage>1807</fpage>
            <page-range>1807-1815</page-range>
            <pub-id pub-id-type="pmid">32628784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Exploration of restless legs syndrome under the new concept: A review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2022</year>
            <month>Dec</month>
            <day>16</day>
            <volume>101</volume>
            <issue>50</issue>
            <fpage>e32324</fpage>
            <pub-id pub-id-type="pmid">36550837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evoy</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Peckham</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Covvey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tidgewell</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Gabapentinoid Pharmacology in the Context of Emerging Misuse Liability.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>61 Suppl 2</volume>
            <fpage>S89</fpage>
            <page-range>S89-S99</page-range>
            <pub-id pub-id-type="pmid">34396549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duflou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Peacock</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lappin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000-2020.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>60</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-310</page-range>
            <pub-id pub-id-type="pmid">34402696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tharp</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hobron</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Gabapentin-related Deaths: Patterns of Abuse and Postmortem Levels.</article-title>
            <source>J Forensic Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>1105</fpage>
            <page-range>1105-1111</page-range>
            <pub-id pub-id-type="pmid">30731020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Falconi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tattoli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Brunetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Prisco</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Gherzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marazzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marengo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serra</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tamagnone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Formica</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Rhabdomyolysis from gabapentin: a case report].</article-title>
            <source>G Ital Nefrol</source>
            <year>2015</year>
            <season>Mar-Apr</season>
            <volume>32</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">26005946</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choi</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>A case of gabapentin-induced rhabdomyolysis requiring renal replacement therapy.</article-title>
            <source>Hemodial Int</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>E4</fpage>
            <page-range>E4-E8</page-range>
            <pub-id pub-id-type="pmid">27389284</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22015.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouchard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yates</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Calello</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ostermann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ghannoum</surname>
                <given-names>M</given-names>
              </name>
              <collab>EXTRIP Workgroup</collab>
            </person-group>
            <article-title>Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>79</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-104</page-range>
            <pub-id pub-id-type="pmid">34799138</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
